Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 18:53 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3Active, not recruitingINTERVENTIONAL

Brain Activation and Satiety in Children 2

ClinicalTrials.gov · NCT04520490 · Registry updated: 2026-01-05

Condition / research focus: Childhood Obesity
Sponsor: Seattle Children's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2021-01-28. Completion: 2026-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Family Based Behavioral Treatment (behavioral)
Exenatide 2 mg [Bydureon] (drug) — also listed as: Bydureon®
Placebo (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Seattle Children's Hospital
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

ClinicalTrials.gov · NCT07309094 · Registry updated: 2025-12-30

Condition / research focus: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2
Sponsor: Cardenal Herrera University
Countries with listed sites: Spain
Registry dates and results: Start: 2023-09-15. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug) — also listed as: semaglutide, liraglutide, dulaglutide, exenatide
SGLT2 inhibitor (drug) — also listed as: dapagliflozin, empagliflozin, canagliflozin
Tirzepatide (drug)
Other drugs (drug) — also listed as: ARBs, ACE inhibitors, Metformin, DPP4i, non steroidal mineralocorticoid receptor agonists

Where the study takes place — 1 listed sites

Vithas Valencia Consuelo
Valencia, Valencia, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

ClinicalTrials.gov · NCT05073692 · Registry updated: 2025-11-21

Condition / research focus: Type 2 Diabetes Mellitus; Cardiovascular Diseases
Sponsor: Kaiser Permanente
Countries with listed sites: United States
Registry dates and results: Start: 2021-07-01. Completion: 2025-03-12 (may be estimated). Results are posted in this registry.

Products and interventions (14)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SU (drug)
DPP4 (drug)
SGLT2i (drug)
GLP-1RA (drug)
SGLT2i or GLP-1RA (drug)
Linagliptin (DPP4) (drug)
Exenatide (GLP-1RA) (drug)
Liraglutide (GLP-1RA) (drug)
Empagliflozin (SGLT2i) (drug)
Glimepiride (SU) (drug)
Glipizide (SU) (drug)
Glimepiride (SU) or Glipizide (SU) (drug)
SU or DPP4 (excluding saxagliptin and alogliptin) (drug)
Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) (drug)

Where the study takes place — 6 listed sites

Kaiser Permanente Southern California
Pasadena, California, United States
Site recruitment: Not reported
Romain S. Neugebauer
Pleasanton, California, United States
Site recruitment: Not reported
Kaiser Permanente Hawaii
Honolulu, Hawaii, United States
Site recruitment: Not reported
Henry Ford Health System
Detroit, Michigan, United States
Site recruitment: Not reported
HealthPartners Institute
Bloomington, Minnesota, United States
Site recruitment: Not reported
Geisinger
Danville, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableActive, not recruitingOBSERVATIONAL

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

ClinicalTrials.gov · NCT07188545 · Registry updated: 2025-09-23

Condition / research focus: Cardiovascular Kidney Metabolic Syndrome
Sponsor: Ohio State University
Countries with listed sites: United States
Registry dates and results: Start: 2025-09-15. Completion: 2029-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Intervention (drug)
Active Comparator (drug)

Where the study takes place — 1 listed sites

Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

ClinicalTrials.gov · NCT05670379 · Registry updated: 2025-09-23

Condition / research focus: Overweight and Obesity; Type2diabetes
Sponsor: Vivani Medical, Inc
Countries with listed sites: Australia
Registry dates and results: Start: 2024-12-20. Completion: 2025-08-21 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide Implant (combination_product) — also listed as: NPM115/NPM119
Bydureon BCise (exenatide extended release) (drug)
Semaglutide, 1.0 mg/mL (drug) — also listed as: Wegovy, Ozempic

Where the study takes place — 1 listed sites

CMax
Adelaide, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

ClinicalTrials.gov · NCT06254014 · Registry updated: 2025-09-18

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Beijing Dongfang Biotech Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-07-10. Completion: 2026-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exendin-4 Fc fusion protein injection (drug) — also listed as: JY09(1.2mg)
Exendin-4 Fc fusion protein injection (drug) — also listed as: JY09(2.4mg)
Placebo (drug) — also listed as: Injection mimetic

Where the study takes place — 1 listed sites

Peking University People's Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

ClinicalTrials.gov · NCT06256419 · Registry updated: 2025-09-18

Condition / research focus: Type 2 Diabetes Mellitus; Susceptibility, Genetic
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Countries with listed sites: China
Registry dates and results: Start: 2024-01-01. Completion: 2028-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)
responders group and nonresponders group (drug)

Where the study takes place — 1 listed sites

China, Jiangsu, Department of Endocrinology
Xuzhou, China, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

ClinicalTrials.gov · NCT06257966 · Registry updated: 2025-09-17

Condition / research focus: Type2 Diabetes Mellitus
Sponsor: Beijing Dongfang Biotech Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-07-17. Completion: 2026-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exendin-4 Fc fusion protein injection(1.2mg） (drug) — also listed as: JY09(1.2mg)
Exendin-4 Fc fusion protein injection（2.4mg） (drug) — also listed as: JY09(2.4mg)
Dulaglutide (drug)
Metformin (drug)

Where the study takes place — 1 listed sites

Peking University First Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

Pharmacogenomics of GLP1 Receptor Agonists

ClinicalTrials.gov · NCT05762744 · Registry updated: 2025-07-01

Condition / research focus: Type 2 Diabetes
Sponsor: University of Maryland, Baltimore
Countries with listed sites: United States
Registry dates and results: Start: 2016-06-01. Completion: 2022-10-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide Injection (before the first FSIGT) (drug) — also listed as: BYETTA, Exenatide
Exenatide injection before the second FSIGT) (drug) — also listed as: BYETTA, Exenatide

Where the study takes place — 1 listed sites

Amish Research Clinic
Lancaster, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

ClinicalTrials.gov · NCT04431713 · Registry updated: 2025-06-27

Condition / research focus: Multiple System Atrophy
Sponsor: University College, London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-09-16. Completion: 2024-03-22 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide Pen Injector [Bydureon] (drug)

Where the study takes place — 1 listed sites

Leonard Wolfson Experimental Neurology Centre, National Hospital of Neurology and Neurosurgery, UCLH NHS Foundation trust
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

ClinicalTrials.gov · NCT03492580 · Registry updated: 2025-06-25

Condition / research focus: Diabetes Mellitus, Type 2; Cardiovascular Diseases
Sponsor: Janssen Research & Development, LLC
Countries with listed sites: United States
Registry dates and results: Start: 2018-02-22. Completion: 2018-06-25 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Canagliflozin (drug)
Empagliflozin (drug)
Dapagliflozin (drug)
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (drug)
Glucagon-like Peptide-1 (GLP-1) Agonist (drug)
Anti-hyperglycemic Agents (AHA) (drug)
Thiazolidinediones (TZD) (drug)
Sulfonylureas (SU) (drug)
Insulin (drug)

Where the study takes place — 1 listed sites

Janssen Investigative Site
Titusville, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.

ClinicalTrials.gov · NCT06888167 · Registry updated: 2025-03-21

Condition / research focus: Healthy Volunteer
Sponsor: Azienda Ospedaliero-Universitaria di Parma
Countries with listed sites: Italy
Registry dates and results: Start: 2024-10-14. Completion: 2026-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Study setting (other)

Where the study takes place — 1 listed sites

Azienda Ospedaliero-Universitaria di Parma
Parma, PR, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus

ClinicalTrials.gov · NCT05662189 · Registry updated: 2025-03-18

Condition / research focus: Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism
Sponsor: Azienda Ospedaliero-Universitaria di Parma
Countries with listed sites: Italy
Registry dates and results: Start: 2022-03-15. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

68Ga-exendin-4 (drug)
mixed meal test (other)

Where the study takes place — 1 listed sites

Azienda Ospedaliero Universitaria di Parma
Parma, Pr, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

ClinicalTrials.gov · NCT04307797 · Registry updated: 2024-09-19

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2022-01-18. Completion: 2022-10-07 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

0.9% Sodium-chloride (drug)
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min (drug) — also listed as: Byetta
Glucagon 12.5ng/kg/min and 0.9% saline (drug)
0.9% Sodium-chloride (drug)
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min (drug)
Glucagon 12.5ng/kg/min (drug)

Where the study takes place — 1 listed sites

Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge
Cambridge, Cambridgeshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

ClinicalTrials.gov · NCT04154072 · Registry updated: 2024-09-19

Condition / research focus: Parkinson Disease
Sponsor: Neuraly, Inc.
Countries with listed sites: Canada · United States
Registry dates and results: Start: 2020-02-27. Completion: 2023-02-14 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NLY01 (drug)
Vehicle (drug)

Where the study takes place — 61 listed sites

University of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute
Phoenix, Arizona, United States
Site recruitment: Not reported
Movement Disorders Center
Scottsdale, Arizona, United States
Site recruitment: Not reported
Mayo Clinic Arizona, Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
Site recruitment: Not reported
Banner Sun Health Research Institute
Sun City, Arizona, United States
Site recruitment: Not reported
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Site recruitment: Not reported
University of California, Irvine
Irvine, California, United States
Site recruitment: Not reported
Keck School of Medicine of USC/University of Southern California
Los Angeles, California, United States
Site recruitment: Not reported
University of California, Los Angeles, Center for Neurotherapeutics
Los Angeles, California, United States
Site recruitment: Not reported
SC3 Research
Pasadena, California, United States
Site recruitment: Not reported
University of California Davis Health
Sacramento, California, United States
Site recruitment: Not reported
University of California, San Francisco
San Francisco, California, United States
Site recruitment: Not reported
University of Colorado
Denver, Colorado, United States
Site recruitment: Not reported
Rocky Mountain Movement Disorder Center
Englewood, Colorado, United States
Site recruitment: Not reported
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States
Site recruitment: Not reported
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Parkinson's Disease and Movement Disorder Center
Boca Raton, Florida, United States
Site recruitment: Not reported
Nova Clinical Research
Bradenton, Florida, United States
Site recruitment: Not reported
University of Florida
Gainesville, Florida, United States
Site recruitment: Not reported
Infinity Clinical Research
Hollywood, Florida, United States
Site recruitment: Not reported
Mayo Clinic Florida
Jacksonville, Florida, United States
Site recruitment: Not reported
Visionary Investigators Network
Miami, Florida, United States
Site recruitment: Not reported
University of Miami
Miami, Florida, United States
Site recruitment: Not reported
Renstar Medical Research
Ocala, Florida, United States
Site recruitment: Not reported
University of South Florida
Tampa, Florida, United States
Site recruitment: Not reported
Charter Research
Winter Park, Florida, United States
Site recruitment: Not reported
Augusta University
Augusta, Georgia, United States
Site recruitment: Not reported
NeuroStudies
Decatur, Georgia, United States
Site recruitment: Not reported
Northwestern Medical Group Neurology Clinic
Chicago, Illinois, United States
Site recruitment: Not reported
Rush University Medical Center
Chicago, Illinois, United States
Site recruitment: Not reported
SIU Medicine
Springfield, Illinois, United States
Site recruitment: Not reported
University of Kansas Medical Center
Kansas City, Kansas, United States
Site recruitment: Not reported
University of Maryland, Neurology Ambulatory Center, Maryland Parkinson's Disease and Movement Disorder Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Site recruitment: Not reported
Massachusetts General Hospital Clinical Trials Pharmacy
Boston, Massachusetts, United States
Site recruitment: Not reported
Boston University Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
University of Michigan Hospital
Ann Arbor, Michigan, United States
Site recruitment: Not reported
Quest Research Institute
Farmington Hills, Michigan, United States
Site recruitment: Not reported
Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan, United States
Site recruitment: Not reported
Struthers Parkinson's Center
Golden Valley, Minnesota, United States
Site recruitment: Not reported
University of Minnesota Delaware Clinical Research Unit
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Neurology Specialists of Monmouth County
West Long Branch, New Jersey, United States
Site recruitment: Not reported
NYU Langone Medical Center, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders
New York, New York, United States
Site recruitment: Not reported
Neurological Institute, Columbia University Medical Center
New York, New York, United States
Site recruitment: Not reported
UNC CTRC
Chapel Hill, North Carolina, United States
Site recruitment: Not reported
Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Raleigh Neurology
Raleigh, North Carolina, United States
Site recruitment: Not reported
Wake Forest Baptist Health Sciences
Winston-Salem, North Carolina, United States
Site recruitment: Not reported
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Site recruitment: Not reported
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Site recruitment: Not reported
University of Toledo, Gardner-McMaster Parkinson Center
Toledo, Ohio, United States
Site recruitment: Not reported
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma, United States
Site recruitment: Not reported
Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Rhode Island Hospital
Providence, Rhode Island, United States
Site recruitment: Not reported
Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported
University of Virginia
Charlottesville, Virginia, United States
Site recruitment: Not reported
Booth Gardner Parkinson's Care Center
Kirkland, Washington, United States
Site recruitment: Not reported
Froedtert Hospital
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
Toronto Western Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

ClinicalTrials.gov · NCT01107717 · Registry updated: 2024-09-05

Condition / research focus: Diabetes
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2009-01. Completion: 2023-02-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

metformin\pioglitazone\exenatide (drug)
metformin, glyburide and glargine (drug)

Where the study takes place — 1 listed sites

Texas Diabetes Institute
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

ClinicalTrials.gov · NCT02673931 · Registry updated: 2024-08-28

Condition / research focus: Coronary Disease; Shock, Cardiogenic; Renal Failure; Stroke; Brain Injury; Aortic Valve Disease
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2016-02. Completion: 2024-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Byetta (Lilly, Exenatide) (drug) — also listed as: GLP-1 agonist
Conoxia (AGA, oxygen) (drug) — also listed as: Oxygen
20% Human Albumin (drug) — also listed as: Albumin

Where the study takes place — 1 listed sites

Rigshospitalet - Copenhagen University Hospital
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

ClinicalTrials.gov · NCT06247748 · Registry updated: 2024-08-21

Condition / research focus: Diabetes Mellitus, Type 2; Overweight
Sponsor: Beijing Dongfang Biotech Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2023-10-19. Completion: 2024-04-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exendin-4 Fc fusion protein (JY09) injection (drug) — also listed as: JY09
Metformin Hydrochloride tablet (drug) — also listed as: Metformin
Rosuvastatin calcium tablets (drug) — also listed as: Rosuvastatin
Digoxin tablet (drug) — also listed as: digoxin

Where the study takes place — 1 listed sites

Peking University Third Hospital drug clinical trial Institute
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

ClinicalTrials.gov · NCT06449235 · Registry updated: 2024-07-16

Condition / research focus: Type2diabetes
Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Countries with listed sites: Bangladesh
Registry dates and results: Start: 2024-09. Completion: 2025-06 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Omarigliptin (drug)
Sulphonylureas (drug)
Metformin (drug)
Other DPP4-i (drug)
Thiazolidinediones (drug)
Alpha-Glucosidase Inhibitor (drug)
Glucagon-Like Peptide-1 (drug)
Receptor Agonists (GLP1RA) (drug)
SGLT2 inhibitors (drug)

Where the study takes place — 1 listed sites

BIRDEM General Hospital
Dhaka, Bangladesh
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Liver and Fat Regulation in Overweight Adolescent Girls

ClinicalTrials.gov · NCT02157974 · Registry updated: 2024-06-04

Condition / research focus: Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity
Sponsor: University of Colorado, Denver
Countries with listed sites: United States
Registry dates and results: Start: 2014-08. Completion: 2022-12 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Byetta 5Mcg Pen Injection (drug) — also listed as: Exenatide

Where the study takes place — 1 listed sites

University of Colorado Anshutz Medical Campus/Children's Hospital Colorado
Aurora, Colorado, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 18:53 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3Active, not recruitingINTERVENTIONAL

Brain Activation and Satiety in Children 2

ClinicalTrials.gov · NCT04520490 · Registry updated: 2026-01-05

Condition / research focus: Childhood Obesity
Sponsor: Seattle Children's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2021-01-28. Completion: 2026-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Family Based Behavioral Treatment (behavioral)
Exenatide 2 mg [Bydureon] (drug) — also listed as: Bydureon®
Placebo (drug)

Where the study takes place — 1 listed sites

Seattle Children's Hospital
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

ClinicalTrials.gov · NCT07309094 · Registry updated: 2025-12-30

Condition / research focus: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2
Sponsor: Cardenal Herrera University
Countries with listed sites: Spain
Registry dates and results: Start: 2023-09-15. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug) — also listed as: semaglutide, liraglutide, dulaglutide, exenatide
SGLT2 inhibitor (drug) — also listed as: dapagliflozin, empagliflozin, canagliflozin
Tirzepatide (drug)
Other drugs (drug) — also listed as: ARBs, ACE inhibitors, Metformin, DPP4i, non steroidal mineralocorticoid receptor agonists

Where the study takes place — 1 listed sites

Vithas Valencia Consuelo
Valencia, Valencia, Spain
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

ClinicalTrials.gov · NCT05073692 · Registry updated: 2025-11-21

Condition / research focus: Type 2 Diabetes Mellitus; Cardiovascular Diseases
Sponsor: Kaiser Permanente
Countries with listed sites: United States
Registry dates and results: Start: 2021-07-01. Completion: 2025-03-12 (may be estimated). Results are posted in this registry.

Products and interventions (14)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SU (drug)
DPP4 (drug)
SGLT2i (drug)
GLP-1RA (drug)
SGLT2i or GLP-1RA (drug)
Linagliptin (DPP4) (drug)
Exenatide (GLP-1RA) (drug)
Liraglutide (GLP-1RA) (drug)
Empagliflozin (SGLT2i) (drug)
Glimepiride (SU) (drug)
Glipizide (SU) (drug)
Glimepiride (SU) or Glipizide (SU) (drug)
SU or DPP4 (excluding saxagliptin and alogliptin) (drug)
Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) (drug)

Where the study takes place — 6 listed sites

Kaiser Permanente Southern California
Pasadena, California, United States
Site recruitment: Not reported
Romain S. Neugebauer
Pleasanton, California, United States
Site recruitment: Not reported
Kaiser Permanente Hawaii
Honolulu, Hawaii, United States
Site recruitment: Not reported
Henry Ford Health System
Detroit, Michigan, United States
Site recruitment: Not reported
HealthPartners Institute
Bloomington, Minnesota, United States
Site recruitment: Not reported
Geisinger
Danville, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableActive, not recruitingOBSERVATIONAL

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

ClinicalTrials.gov · NCT07188545 · Registry updated: 2025-09-23

Condition / research focus: Cardiovascular Kidney Metabolic Syndrome
Sponsor: Ohio State University
Countries with listed sites: United States
Registry dates and results: Start: 2025-09-15. Completion: 2029-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Intervention (drug)
Active Comparator (drug)

Where the study takes place — 1 listed sites

Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

ClinicalTrials.gov · NCT05670379 · Registry updated: 2025-09-23

Condition / research focus: Overweight and Obesity; Type2diabetes
Sponsor: Vivani Medical, Inc
Countries with listed sites: Australia
Registry dates and results: Start: 2024-12-20. Completion: 2025-08-21 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide Implant (combination_product) — also listed as: NPM115/NPM119
Bydureon BCise (exenatide extended release) (drug)
Semaglutide, 1.0 mg/mL (drug) — also listed as: Wegovy, Ozempic

Where the study takes place — 1 listed sites

CMax
Adelaide, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

ClinicalTrials.gov · NCT06254014 · Registry updated: 2025-09-18

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Beijing Dongfang Biotech Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-07-10. Completion: 2026-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exendin-4 Fc fusion protein injection (drug) — also listed as: JY09(1.2mg)
Exendin-4 Fc fusion protein injection (drug) — also listed as: JY09(2.4mg)
Placebo (drug) — also listed as: Injection mimetic

Where the study takes place — 1 listed sites

Peking University People's Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

ClinicalTrials.gov · NCT06256419 · Registry updated: 2025-09-18

Condition / research focus: Type 2 Diabetes Mellitus; Susceptibility, Genetic
Sponsor: The Affiliated Hospital of Xuzhou Medical University
Countries with listed sites: China
Registry dates and results: Start: 2024-01-01. Completion: 2028-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 receptor agonist (drug)
responders group and nonresponders group (drug)

Where the study takes place — 1 listed sites

China, Jiangsu, Department of Endocrinology
Xuzhou, China, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

ClinicalTrials.gov · NCT06257966 · Registry updated: 2025-09-17

Condition / research focus: Type2 Diabetes Mellitus
Sponsor: Beijing Dongfang Biotech Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-07-17. Completion: 2026-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exendin-4 Fc fusion protein injection(1.2mg） (drug) — also listed as: JY09(1.2mg)
Exendin-4 Fc fusion protein injection（2.4mg） (drug) — also listed as: JY09(2.4mg)
Dulaglutide (drug)
Metformin (drug)

Where the study takes place — 1 listed sites

Peking University First Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

Pharmacogenomics of GLP1 Receptor Agonists

ClinicalTrials.gov · NCT05762744 · Registry updated: 2025-07-01

Condition / research focus: Type 2 Diabetes
Sponsor: University of Maryland, Baltimore
Countries with listed sites: United States
Registry dates and results: Start: 2016-06-01. Completion: 2022-10-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide Injection (before the first FSIGT) (drug) — also listed as: BYETTA, Exenatide
Exenatide injection before the second FSIGT) (drug) — also listed as: BYETTA, Exenatide

Where the study takes place — 1 listed sites

Amish Research Clinic
Lancaster, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

ClinicalTrials.gov · NCT04431713 · Registry updated: 2025-06-27

Condition / research focus: Multiple System Atrophy
Sponsor: University College, London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-09-16. Completion: 2024-03-22 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide Pen Injector [Bydureon] (drug)

Where the study takes place — 1 listed sites

Leonard Wolfson Experimental Neurology Centre, National Hospital of Neurology and Neurosurgery, UCLH NHS Foundation trust
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

ClinicalTrials.gov · NCT03492580 · Registry updated: 2025-06-25

Condition / research focus: Diabetes Mellitus, Type 2; Cardiovascular Diseases
Sponsor: Janssen Research & Development, LLC
Countries with listed sites: United States
Registry dates and results: Start: 2018-02-22. Completion: 2018-06-25 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Canagliflozin (drug)
Empagliflozin (drug)
Dapagliflozin (drug)
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (drug)
Glucagon-like Peptide-1 (GLP-1) Agonist (drug)
Anti-hyperglycemic Agents (AHA) (drug)
Thiazolidinediones (TZD) (drug)
Sulfonylureas (SU) (drug)
Insulin (drug)

Where the study takes place — 1 listed sites

Janssen Investigative Site
Titusville, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.

ClinicalTrials.gov · NCT06888167 · Registry updated: 2025-03-21

Condition / research focus: Healthy Volunteer
Sponsor: Azienda Ospedaliero-Universitaria di Parma
Countries with listed sites: Italy
Registry dates and results: Start: 2024-10-14. Completion: 2026-02-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Study setting (other)

Where the study takes place — 1 listed sites

Azienda Ospedaliero-Universitaria di Parma
Parma, PR, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus

ClinicalTrials.gov · NCT05662189 · Registry updated: 2025-03-18

Condition / research focus: Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism
Sponsor: Azienda Ospedaliero-Universitaria di Parma
Countries with listed sites: Italy
Registry dates and results: Start: 2022-03-15. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

68Ga-exendin-4 (drug)
mixed meal test (other)

Where the study takes place — 1 listed sites

Azienda Ospedaliero Universitaria di Parma
Parma, Pr, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

ClinicalTrials.gov · NCT04307797 · Registry updated: 2024-09-19

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2022-01-18. Completion: 2022-10-07 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

0.9% Sodium-chloride (drug)
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min (drug) — also listed as: Byetta
Glucagon 12.5ng/kg/min and 0.9% saline (drug)
0.9% Sodium-chloride (drug)
Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min (drug)
Glucagon 12.5ng/kg/min (drug)

Where the study takes place — 1 listed sites

Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge
Cambridge, Cambridgeshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

ClinicalTrials.gov · NCT04154072 · Registry updated: 2024-09-19

Condition / research focus: Parkinson Disease
Sponsor: Neuraly, Inc.
Countries with listed sites: Canada · United States
Registry dates and results: Start: 2020-02-27. Completion: 2023-02-14 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NLY01 (drug)
Vehicle (drug)

Where the study takes place — 61 listed sites

University of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute
Phoenix, Arizona, United States
Site recruitment: Not reported
Movement Disorders Center
Scottsdale, Arizona, United States
Site recruitment: Not reported
Mayo Clinic Arizona, Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
Site recruitment: Not reported
Banner Sun Health Research Institute
Sun City, Arizona, United States
Site recruitment: Not reported
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Site recruitment: Not reported
University of California, Irvine
Irvine, California, United States
Site recruitment: Not reported
Keck School of Medicine of USC/University of Southern California
Los Angeles, California, United States
Site recruitment: Not reported
University of California, Los Angeles, Center for Neurotherapeutics
Los Angeles, California, United States
Site recruitment: Not reported
SC3 Research
Pasadena, California, United States
Site recruitment: Not reported
University of California Davis Health
Sacramento, California, United States
Site recruitment: Not reported
University of California, San Francisco
San Francisco, California, United States
Site recruitment: Not reported
University of Colorado
Denver, Colorado, United States
Site recruitment: Not reported
Rocky Mountain Movement Disorder Center
Englewood, Colorado, United States
Site recruitment: Not reported
Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States
Site recruitment: Not reported
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Parkinson's Disease and Movement Disorder Center
Boca Raton, Florida, United States
Site recruitment: Not reported
Nova Clinical Research
Bradenton, Florida, United States
Site recruitment: Not reported
University of Florida
Gainesville, Florida, United States
Site recruitment: Not reported
Infinity Clinical Research
Hollywood, Florida, United States
Site recruitment: Not reported
Mayo Clinic Florida
Jacksonville, Florida, United States
Site recruitment: Not reported
Visionary Investigators Network
Miami, Florida, United States
Site recruitment: Not reported
University of Miami
Miami, Florida, United States
Site recruitment: Not reported
Renstar Medical Research
Ocala, Florida, United States
Site recruitment: Not reported
University of South Florida
Tampa, Florida, United States
Site recruitment: Not reported
Charter Research
Winter Park, Florida, United States
Site recruitment: Not reported
Augusta University
Augusta, Georgia, United States
Site recruitment: Not reported
NeuroStudies
Decatur, Georgia, United States
Site recruitment: Not reported
Northwestern Medical Group Neurology Clinic
Chicago, Illinois, United States
Site recruitment: Not reported
Rush University Medical Center
Chicago, Illinois, United States
Site recruitment: Not reported
SIU Medicine
Springfield, Illinois, United States
Site recruitment: Not reported
University of Kansas Medical Center
Kansas City, Kansas, United States
Site recruitment: Not reported
University of Maryland, Neurology Ambulatory Center, Maryland Parkinson's Disease and Movement Disorder Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Site recruitment: Not reported
Massachusetts General Hospital Clinical Trials Pharmacy
Boston, Massachusetts, United States
Site recruitment: Not reported
Boston University Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
University of Michigan Hospital
Ann Arbor, Michigan, United States
Site recruitment: Not reported
Quest Research Institute
Farmington Hills, Michigan, United States
Site recruitment: Not reported
Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan, United States
Site recruitment: Not reported
Struthers Parkinson's Center
Golden Valley, Minnesota, United States
Site recruitment: Not reported
University of Minnesota Delaware Clinical Research Unit
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Neurology Specialists of Monmouth County
West Long Branch, New Jersey, United States
Site recruitment: Not reported
NYU Langone Medical Center, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders
New York, New York, United States
Site recruitment: Not reported
Neurological Institute, Columbia University Medical Center
New York, New York, United States
Site recruitment: Not reported
UNC CTRC
Chapel Hill, North Carolina, United States
Site recruitment: Not reported
Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Raleigh Neurology
Raleigh, North Carolina, United States
Site recruitment: Not reported
Wake Forest Baptist Health Sciences
Winston-Salem, North Carolina, United States
Site recruitment: Not reported
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Site recruitment: Not reported
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Site recruitment: Not reported
University of Toledo, Gardner-McMaster Parkinson Center
Toledo, Ohio, United States
Site recruitment: Not reported
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma, United States
Site recruitment: Not reported
Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Rhode Island Hospital
Providence, Rhode Island, United States
Site recruitment: Not reported
Baylor College of Medicine
Houston, Texas, United States
Site recruitment: Not reported
University of Virginia
Charlottesville, Virginia, United States
Site recruitment: Not reported
Booth Gardner Parkinson's Care Center
Kirkland, Washington, United States
Site recruitment: Not reported
Froedtert Hospital
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
Toronto Western Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

ClinicalTrials.gov · NCT01107717 · Registry updated: 2024-09-05

Condition / research focus: Diabetes
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2009-01. Completion: 2023-02-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

metformin\pioglitazone\exenatide (drug)
metformin, glyburide and glargine (drug)

Where the study takes place — 1 listed sites

Texas Diabetes Institute
San Antonio, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

ClinicalTrials.gov · NCT02673931 · Registry updated: 2024-08-28

Condition / research focus: Coronary Disease; Shock, Cardiogenic; Renal Failure; Stroke; Brain Injury; Aortic Valve Disease
Sponsor: Copenhagen University Hospital, Rigshospitalet
Countries with listed sites: Denmark
Registry dates and results: Start: 2016-02. Completion: 2024-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Byetta (Lilly, Exenatide) (drug) — also listed as: GLP-1 agonist
Conoxia (AGA, oxygen) (drug) — also listed as: Oxygen
20% Human Albumin (drug) — also listed as: Albumin

Where the study takes place — 1 listed sites

Rigshospitalet - Copenhagen University Hospital
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

ClinicalTrials.gov · NCT06247748 · Registry updated: 2024-08-21

Condition / research focus: Diabetes Mellitus, Type 2; Overweight
Sponsor: Beijing Dongfang Biotech Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2023-10-19. Completion: 2024-04-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exendin-4 Fc fusion protein (JY09) injection (drug) — also listed as: JY09
Metformin Hydrochloride tablet (drug) — also listed as: Metformin
Rosuvastatin calcium tablets (drug) — also listed as: Rosuvastatin
Digoxin tablet (drug) — also listed as: digoxin

Where the study takes place — 1 listed sites

Peking University Third Hospital drug clinical trial Institute
Beijing, Beijing Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

ClinicalTrials.gov · NCT06449235 · Registry updated: 2024-07-16

Condition / research focus: Type2diabetes
Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Countries with listed sites: Bangladesh
Registry dates and results: Start: 2024-09. Completion: 2025-06 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Omarigliptin (drug)
Sulphonylureas (drug)
Metformin (drug)
Other DPP4-i (drug)
Thiazolidinediones (drug)
Alpha-Glucosidase Inhibitor (drug)
Glucagon-Like Peptide-1 (drug)
Receptor Agonists (GLP1RA) (drug)
SGLT2 inhibitors (drug)

Where the study takes place — 1 listed sites

BIRDEM General Hospital
Dhaka, Bangladesh
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Liver and Fat Regulation in Overweight Adolescent Girls

ClinicalTrials.gov · NCT02157974 · Registry updated: 2024-06-04

Condition / research focus: Hepatic Steatosis; Polycystic Ovarian Syndrome; Obesity
Sponsor: University of Colorado, Denver
Countries with listed sites: United States
Registry dates and results: Start: 2014-08. Completion: 2022-12 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Byetta 5Mcg Pen Injection (drug) — also listed as: Exenatide

Where the study takes place — 1 listed sites

University of Colorado Anshutz Medical Campus/Children's Hospital Colorado
Aurora, Colorado, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →